JP7233375B2 - リソソーム障害を治療する方法 - Google Patents

リソソーム障害を治療する方法 Download PDF

Info

Publication number
JP7233375B2
JP7233375B2 JP2019550825A JP2019550825A JP7233375B2 JP 7233375 B2 JP7233375 B2 JP 7233375B2 JP 2019550825 A JP2019550825 A JP 2019550825A JP 2019550825 A JP2019550825 A JP 2019550825A JP 7233375 B2 JP7233375 B2 JP 7233375B2
Authority
JP
Japan
Prior art keywords
disease
cells
vector
ctns
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019550825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511470A5 (https=
JP2020511470A (ja
Inventor
ステファニー シェルキ
エリック アドラー
シルビア エバンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020511470A publication Critical patent/JP2020511470A/ja
Publication of JP2020511470A5 publication Critical patent/JP2020511470A5/ja
Priority to JP2023005909A priority Critical patent/JP2023052475A/ja
Application granted granted Critical
Publication of JP7233375B2 publication Critical patent/JP7233375B2/ja
Priority to JP2025000101A priority patent/JP2025039642A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
JP2019550825A 2017-03-15 2018-03-15 リソソーム障害を治療する方法 Active JP7233375B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023005909A JP2023052475A (ja) 2017-03-15 2023-01-18 リソソーム障害を治療する方法
JP2025000101A JP2025039642A (ja) 2017-03-15 2025-01-06 リソソーム障害を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471741P 2017-03-15 2017-03-15
US62/471,741 2017-03-15
US201762507713P 2017-05-17 2017-05-17
US62/507,713 2017-05-17
PCT/US2018/022598 WO2018170239A1 (en) 2017-03-15 2018-03-15 Methods of treating lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023005909A Division JP2023052475A (ja) 2017-03-15 2023-01-18 リソソーム障害を治療する方法

Publications (3)

Publication Number Publication Date
JP2020511470A JP2020511470A (ja) 2020-04-16
JP2020511470A5 JP2020511470A5 (https=) 2021-04-15
JP7233375B2 true JP7233375B2 (ja) 2023-03-06

Family

ID=63523990

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019550825A Active JP7233375B2 (ja) 2017-03-15 2018-03-15 リソソーム障害を治療する方法
JP2023005909A Pending JP2023052475A (ja) 2017-03-15 2023-01-18 リソソーム障害を治療する方法
JP2025000101A Pending JP2025039642A (ja) 2017-03-15 2025-01-06 リソソーム障害を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023005909A Pending JP2023052475A (ja) 2017-03-15 2023-01-18 リソソーム障害を治療する方法
JP2025000101A Pending JP2025039642A (ja) 2017-03-15 2025-01-06 リソソーム障害を治療する方法

Country Status (8)

Country Link
US (2) US11806367B2 (https=)
EP (1) EP3596111A4 (https=)
JP (3) JP7233375B2 (https=)
CN (1) CN110418800A (https=)
AU (2) AU2018236353B2 (https=)
CA (1) CA3056617A1 (https=)
IL (1) IL269082A (https=)
WO (1) WO2018170239A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056617A1 (en) 2017-03-15 2018-09-20 The Regents Of The University Of California Methods of treating lysosomal disorders
KR102918544B1 (ko) 2018-07-12 2026-01-27 로켓 파마슈티컬스, 리미티드 다논병을 치료하기 위한 유전자 요법 벡터
CN109880849B (zh) * 2019-01-03 2023-04-11 四川大学 靶向肿瘤相关巨噬细胞的GHOST-shRNA表达载体复合物及其应用
WO2020160458A1 (en) 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
WO2020179931A1 (ja) * 2019-03-07 2020-09-10 国立大学法人 東京医科歯科大学 ハイスループット遺伝子編集技術
US12319928B2 (en) * 2019-03-21 2025-06-03 The Regents Of The University Of Colorado, A Body Corporate Methods of treating Danon disease
WO2020210218A1 (en) * 2019-04-12 2020-10-15 The Regents Of The University Of California Methods for treating inherited eye defects
WO2021073607A1 (en) * 2019-10-17 2021-04-22 Westlake Therapeutics (Hangzhou) Co. Limited Engineering red blood cells for treatment of lysosomal storage diseases
GB202003536D0 (en) * 2020-03-11 2020-04-29 Ucl Business Ltd Gene therapy
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN114934066B (zh) * 2022-04-28 2024-10-18 深圳临研医学有限公司 石骨症的基因编辑体系及其应用
CN118388623B (zh) * 2024-06-28 2024-10-08 首都医科大学 Sialin蛋白在调控细胞线粒体功能中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527881A (ja) 2012-07-11 2015-09-24 サンガモ バイオサイエンシーズ， インコーポレイテッド リソソーム貯蔵疾患の処置のための方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
HK1208371A1 (en) 2012-10-09 2016-03-04 桑比欧公司 Methods and compositions for treatment of retinal degeneration
US10155794B2 (en) 2013-07-16 2018-12-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to CEP290
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
PE20180772A1 (es) * 2015-07-01 2018-05-07 Univ California Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversa
US10670862B2 (en) 2015-07-02 2020-06-02 Microsoft Technology Licensing, Llc Diffractive optical elements with asymmetric profiles
JP7089282B2 (ja) * 2015-07-20 2022-06-22 アンジオクライン・バイオサイエンス・インコーポレイテッド 幹細胞移植のための方法および組成物
CA3056617A1 (en) 2017-03-15 2018-09-20 The Regents Of The University Of California Methods of treating lysosomal disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527881A (ja) 2012-07-11 2015-09-24 サンガモ バイオサイエンシーズ， インコーポレイテッド リソソーム貯蔵疾患の処置のための方法および組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta，2009年，Vol. 1793，pp. 636-649
Lentiviral Vector-Transduced Hematopoietic Stem Cell Gene Therapy for Cystinosis，Molecular Therapy，2010年，Vol. 18, Supplement 1，pp. S157-S158，408
Molecular Therapy，2013年，Vol. 21, No. 2，pp. 433-444

Also Published As

Publication number Publication date
AU2018236353B2 (en) 2023-12-21
JP2020511470A (ja) 2020-04-16
EP3596111A1 (en) 2020-01-22
IL269082A (en) 2019-11-28
US20240009247A1 (en) 2024-01-11
EP3596111A4 (en) 2021-01-06
AU2024201797A1 (en) 2024-04-11
CA3056617A1 (en) 2018-09-20
AU2018236353A1 (en) 2019-09-26
JP2023052475A (ja) 2023-04-11
CN110418800A (zh) 2019-11-05
US11806367B2 (en) 2023-11-07
WO2018170239A1 (en) 2018-09-20
US20210161966A1 (en) 2021-06-03
JP2025039642A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
JP7233375B2 (ja) リソソーム障害を治療する方法
US12012437B2 (en) Methods of treating mitochondrial disorders
JP7833204B2 (ja) 栄養障害型表皮水疱症治療薬
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
WO2022018884A1 (ja) 栄養障害型表皮水疱症の治療薬
CN113544279A (zh) 包含芳基硫酸酯酶a的重组载体及其在用于治疗异染性脑白质营养不良的干细胞治疗中的用途
JP2025111442A (ja) 最適化されたｒａｇ１欠損遺伝子治療
CA3171432A1 (en) Methods of treating mitochondrial disorders
US20220177918A1 (en) Methods for treating inherited eye defects
HK40016634A (en) Methods of treating lysosomal disorders
Gupta et al. Genome‐Editing Applications in Stem Cell Engineering and Regenerative Medicine
Loperfido et al. PiggyBac transposons for stem cell-based gene therapy of Duchenne muscular dystrophy
JP2024542167A (ja) 眼表面疾患の治療用などの医薬品として使用するための細胞外小胞又はその組成物
Shortall Development of gene therapies for retinal degenerations
Kremer 2nd European Conference and Practical Course–Oral Communications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190927

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230221

R150 Certificate of patent or registration of utility model

Ref document number: 7233375

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250